Literature DB >> 23588707

Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography.

James H Tabibian1, Slobodan I Macura, Steven P O'Hara, Jeff L Fidler, James F Glockner, Naoki Takahashi, Val J Lowe, Bradley J Kemp, Prasanna K Mishra, Pamela S Tietz, Patrick L Splinter, Christy E Trussoni, Nicholas F LaRusso.   

Abstract

The cholangiopathies are a diverse group of biliary tract disorders, many of which lack effective treatment. Murine models are an important tool for studying their pathogenesis, but existing noninvasive methods for assessing biliary disease in vivo are not optimal. Here we report our experience with using micro-computed tomography (microCT) and nuclear magnetic resonance (MR) imaging to develop a technique for live-mouse cholangiography. Using mdr2 knockout (mdr2KO, a model for primary sclerosing cholangitis (PSC)), bile duct-ligated (BDL), and normal mice, we performed in vivo: (1) microCT on a Siemens Inveon PET/CT scanner and (2) MR on a Bruker Avance 16.4 T spectrometer, using Turbo Rapid Acquisition with Relaxation Enhancement, IntraGate Fast Low Angle Shot, and Half-Fourier Acquisition Single-shot Turbo Spin Echo methods. Anesthesia was with 1.5-2.5% isoflurane. Scans were performed with and without contrast agents (iodipamide meglumine (microCT), gadoxetate disodium (MR)). Dissection and liver histology were performed for validation. With microCT, only the gallbladder and extrahepatic bile ducts were visualized despite attempts to optimize timing, route, and dose of contrast. With MR, the gallbladder, extra-, and intrahepatic bile ducts were well-visualized in mdr2KO mice; the cholangiographic appearance was similar to that of PSC (eg, multifocal strictures) and could be improved with contrast administration. In BDL mice, MR revealed cholangiographically distinct progressive dilation of the biliary tree without ductal irregularity. In normal mice, MR allowed visualization of the gallbladder and extrahepatic ducts, but only marginal visualization of the diminutive intrahepatic ducts. One mouse died during microCT and MR imaging, respectively. Both microCT and MR scans could be obtained in ≤20 min. We, therefore, demonstrate that MR cholangiography can be a useful tool for longitudinal studies of the biliary tree in live mice, whereas microCT yields suboptimal duct visualization despite requiring contrast administration. These findings support further development and application of MR cholangiography to the study of mouse models of PSC and other cholangiopathies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23588707      PMCID: PMC3875307          DOI: 10.1038/labinvest.2013.52

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  35 in total

1.  Does intravenous glucagon improve common bile duct visualisation during magnetic resonance cholangiopancreatography? Results in 42 patients.

Authors:  Paras U Dalal; David C Howlett; David F Sallomi; Nigel D Marchbank; Gillian M T Watson; Amanda Marr; Arthur A Dunk; Alastair D Smith
Journal:  Eur J Radiol       Date:  2004-03       Impact factor: 3.528

2.  Dilated biliary tract: evaluation with MR cholangiography with a T2-weighted contrast-enhanced fast sequence.

Authors:  B K Wallner; K A Schumacher; W Weidenmaier; J M Friedrich
Journal:  Radiology       Date:  1991-12       Impact factor: 11.105

3.  Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.

Authors:  K D Lindor
Journal:  N Engl J Med       Date:  1997-03-06       Impact factor: 91.245

4.  The role of bile salt composition in liver pathology of mdr2 (-/-) mice: differences between males and females.

Authors:  C M van Nieuwerk; A K Groen; R Ottenhoff; M van Wijland; M A van den Bergh Weerman; G N Tytgat; J J Offerhaus; R P Oude Elferink
Journal:  J Hepatol       Date:  1997-01       Impact factor: 25.083

5.  Primary sclerosing cholangitis: findings on cholangiography and pancreatography.

Authors:  R L MacCarty; N F LaRusso; R H Wiesner; J Ludwig
Journal:  Radiology       Date:  1983-10       Impact factor: 11.105

6.  Clinicopathologic features of the syndrome of primary sclerosing cholangitis.

Authors:  R H Wiesner; N F LaRusso
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

7.  Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community.

Authors:  Kiran Bambha; W Ray Kim; Jayant Talwalkar; Heidi Torgerson; Joanne T Benson; Terry M Therneau; Edward V Loftus; Barbara P Yawn; E Rolland Dickson; L Joseph Melton
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682

8.  Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.

Authors:  Peter Fickert; Andrea Fuchsbichler; Martin Wagner; Gernot Zollner; Arthur Kaser; Herbert Tilg; Robert Krause; Frank Lammert; Cord Langner; Kurt Zatloukal; Hanns-Ulrich Marschall; Helmut Denk; Michael Trauner
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

9.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

Review 10.  The cholangiopathies: disorders of biliary epithelia.

Authors:  Konstantinos N Lazaridis; Mario Strazzabosco; Nicholas F Larusso
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

View more
  16 in total

Review 1.  Endoscopic management of benign biliary strictures.

Authors:  Kavel H Visrodia; James H Tabibian; Todd H Baron
Journal:  World J Gastrointest Endosc       Date:  2015-08-25

2.  Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.

Authors:  James H Tabibian; Steven P O'Hara; Christy E Trussoni; Pamela S Tietz; Patrick L Splinter; Taofic Mounajjed; Lee R Hagey; Nicholas F LaRusso
Journal:  Hepatology       Date:  2015-08-10       Impact factor: 17.425

Review 3.  Characterization of animal models for primary sclerosing cholangitis (PSC).

Authors:  Peter Fickert; Marion J Pollheimer; Ulrich Beuers; Carolin Lackner; Gideon Hirschfield; Chantal Housset; Verena Keitel; Christoph Schramm; Hanns-Ulrich Marschall; Tom H Karlsen; Espen Melum; Arthur Kaser; Bertus Eksteen; Mario Strazzabosco; Michael Manns; Michael Trauner
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

4.  Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis.

Authors:  James H Tabibian; Steven P O'Hara; Patrick L Splinter; Christy E Trussoni; Nicholas F LaRusso
Journal:  Hepatology       Date:  2014-04-25       Impact factor: 17.425

5.  Primary sclerosing cholangitis: A review and update.

Authors:  James H Tabibian; Christopher L Bowlus
Journal:  Liver Res       Date:  2017-12

6.  Sepsis-3 on the Block: What Does It Mean for Preclinical Sepsis Modeling?

Authors:  Marcin F Osuchowski; Christoph Thiemermann; Daniel G Remick
Journal:  Shock       Date:  2017-05       Impact factor: 3.454

Review 7.  Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.

Authors:  James H Tabibian; Steven P O'Hara; Keith D Lindor
Journal:  Scand J Gastroenterol       Date:  2014-07-03       Impact factor: 2.423

8.  Visualizing surface area and volume of lumens in three dimensions using images from histological sections.

Authors:  David P Livingston; Tan D Tuong; Grace E Kissling; John M Cullen
Journal:  J Microsc       Date:  2014-09-10       Impact factor: 1.758

9.  Lipopolysaccharide (LPS)-Induced Biliary Epithelial Cell NRas Activation Requires Epidermal Growth Factor Receptor (EGFR).

Authors:  Christy E Trussoni; James H Tabibian; Patrick L Splinter; Steven P O'Hara
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

Review 10.  Role of the microbiota and antibiotics in primary sclerosing cholangitis.

Authors:  James H Tabibian; Jayant A Talwalkar; Keith D Lindor
Journal:  Biomed Res Int       Date:  2013-10-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.